NHS National Pharmaceuticals Transition 2021_3
Details
- Buyer
- NHS England
- Value
- GBP 214,113,004
- Topic
- Pharmaceutical products
- Published
- 2 June 2021
- Submission
- 7 July 2021
- Source
- uk:find_a_tender
Tender description
NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633 Lot 1: Hospital Only Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 2: Hospital Only Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Hospital Only Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 4: Oral (plus non-parenteral) products: All regions NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 6: Transition Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 5: Transition Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 7: Transition Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 1: Hospital Only Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 2: Hospital Only Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Hospital Only Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 4: Oral (plus non-parenteral) products: All regions NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 6: Transition Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 5: Transition Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 7: Transition Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)
Timeline
- Completed: Tender published2 June 2021Current notice
- Completed: Submission date7 July 2021
About the buyer
NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Relevant CPV codes
- 33600000 · Pharmaceutical products
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
6 similar open tenders
See more open tenders related to NHS National Pharmaceuticals Transition 2021_3.
- Open tender
IMP Manufacture, Labelling and Packaging DPS
- Open tender
CPH037 - Enhanced Services (Pharmacies)
- Open tender
Potassium iodide tablets 2024-2026
Related buyers
Buyers similar to NHS England.
- 441£232.8m
- 358£99.4m
- 349£15.0bn
- 288£2.8bn
- 254£16.6bn
- 248£888.9m
- 240£507.0m
- 201£1.0bn
- 136£895.2m
- 113£59.4m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
